Dermata Therapeutics (NASDAQ:DRMA) versus AbCellera Biologics (NASDAQ:ABCL) Head to Head Contrast

Dermata Therapeutics (NASDAQ:DRMA) and AbCellera Biologics (NASDAQ:ABCL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability and earnings.

Analyst Ratings

This is a breakdown of current recommendations for Dermata Therapeutics and AbCellera Biologics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dermata Therapeutics	1	0	1	0	2.00
AbCellera Biologics	1	1	4	0	2.50

Dermata Therapeutics presently has a consensus target price of $10.00, suggesting a potential upside of 719.67%. AbCellera Biologics has a consensus target price of $8.40, suggesting a potential upside of 137.29%. Given Dermata Therapeutics’ higher possible upside, analysts clearly believe Dermata Therapeutics is more favorable than AbCellera Biologics.

Profitability

This table compares Dermata Therapeutics and AbCellera Biologics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dermata Therapeutics	N/A	-130.89%	-102.20%
AbCellera Biologics	-198.37%	-15.05%	-10.92%

Earnings & Valuation

This table compares Dermata Therapeutics and AbCellera Biologics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dermata Therapeutics	N/A	N/A	-$7.56 million	($9.33)	-0.13
AbCellera Biologics	$75.13 million	14.28	-$146.41 million	($0.49)	-7.22

Dermata Therapeutics has higher earnings, but lower revenue than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Dermata Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Dermata Therapeutics has a beta of 0.5, indicating that its share price is 50% less volatile than the S&P 500. Comparatively, AbCellera Biologics has a beta of 0.85, indicating that its share price is 15% less volatile than the S&P 500.

Institutional and Insider Ownership

8.7% of Dermata Therapeutics shares are owned by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are owned by institutional investors. 18.5% of Dermata Therapeutics shares are owned by company insiders. Comparatively, 28.9% of AbCellera Biologics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

AbCellera Biologics beats Dermata Therapeutics on 9 of the 13 factors compared between the two stocks.

About Dermata Therapeutics

Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

About AbCellera Biologics

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.